Neuroblastoma and MYCN

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 10, 2013, Pages

  Huang, Miller ^a   Weiss, William A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TUMOR ANTIGEN;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; METASTASIS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; ONCOGENE MYC; PATHOLOGY; PROTEIN STABILITY; REVIEW; RISK FACTOR;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; GENE AMPLIFICATION; GENE EXPRESSION; GENES, MYC; GENETIC MARKERS; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEIN STABILITY; RISK FACTORS; TRANSCRIPTION, GENETIC;

EID: 84885046316     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014415     Document Type: Article

References (198)

1. Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M, Suenaga Y, Nakagawara A. 2011. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its down regulation is associated with unfavorable outcome in neuroblastoma. Clin Cancer Res 17: 6681-6692.
2. Arregui CO, Balsamo J, Lilien J. 2000. Regulation of signaling by protein-tyrosine phosphatases: Potential roles in the nervous system. Neurochem Res 25: 95-105.
3. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, et al. 2005. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253.
4. Au SLK, Wong CCL, Lee JMF, Fan DNY, Tsang FH, Ng IOL, Wong CM. 2012. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor micro-RNAs to promote liver cancer metastasis. Hepatology 56: 622-631.
5. Banelli B, Gelvi I, Di Vinci A, Scaruffi P, Casciano I, Alle-manni G, Bonassi S, Tonini GP, Romani M. 2005. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene24: 5619-5628.
6. Barbero S, Mielgo A, Torres V, Teitz T, Shields DJ, Mikolon D, Bogyo M, Barila D, Lahti JM, Schlaepfer D, et al. 2009. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 69: 3755-3763.
7. Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG, Golubovskaya VM. 2007. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 282: 12503-12516.
8. Bell E, Lunec J, Tweddle DA. 2007. Cell cycle regulation targets of MYCN identified by gene expression microar-rays. Cell Cycle 6: 1249-1256.
9. Benard J. 1995. Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma. Eur J Cancer 31A: 560-564.
10. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, et al. 2004. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64: 8816-8820.
11. F1174L mutation potentiates the oncogenic activ-ityof MYCNin neuroblastoma. Cancer Cell 22: 117-130.
12. Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, et al. 2013. Histone H3.3 mutations drive pediatric glioblasto-ma through upregulation of MYCN. Cancer Discov 3: 512-519.
13. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, et al. 2008. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 7: 2394-2404.
14. Bradner J. 2013. Inhibiting Myc. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.014266.
15. Breit S, Schwab M. 1989. Suppression of MYC by high expression of NMYC in human neuroblastoma cells. J Neurosci Res 24: 21-28.
16. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, et al. 2005. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 24: 336-346.
17. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. 1984. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
18. Buechner J, Einvik C. 2012. N-myc and noncoding RNAs in neuroblastoma. Mol Cancer Res 10: 1243-1253.
19. Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M. 2003. Effects of MYCN antisense oligonucleo-tide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95: 1394-1403.
20. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mossé YP, Kim C, Diskin SJ, Cole KA, et al. Common variations in BARD1 influence suscep tibility to high-risk neuroblastoma. Nat Genet 41: 718-723.
21. Capasso M, Diskin SJ, Totaro F, Longo L, Mariano MD, Russo R, Cimmino F, Hakonarson H, Tonini GP, Devoto M, et al. 2013. Replication of GWAS-identified neuro-blastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis 34: 605-611.
22. Carén H, Kryh H, Nethander M, Sjöberg R-M, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T. High-risk neuroblastoma tumors with 11q-dele- tion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci 107: 4323-4328.
23. Caron H, Spieker N, Godfried M, Veenstra M, van Sluis P, de Kraker J, Voûte P, Versteeg R. 2001. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosomes Cancer 30: 168-174.
24. Carpenter EL, Mossé YP. 2012. Targeting ALK in neuroblas-toma-preclinical and clinical advancements. Nat Rev Clin Oncol 9: 391-399.
25. Kip1. Genes Dev 11: 2335-2346.
26. Casciano I, Banelli B, Croce M, De Ambrosis A, Di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, et al. 2004. Caspase-8 gene expression in neuroblastoma. Ann N Y Acad Sci 1028: 157-167.
27. Cavalieri F, Goldfarb M. 1988. N-myc proto-oncogene expression can induce DNA replication in Balb/c 3T3 fi-broblasts. Oncogene 2: 289-291.
28. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Mat-thay KK, et al. 2012. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med 4: 115-123.
29. Chappell J, Dalton S. 2013. Roles for MYC in the establishment and maintenance ofpluripotency. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.014381.
30. Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, Robertson EJ, Alt FW. 1992. Embryonic lethality in mice homozygous foratargeted disruption of the N-myc gene. Genes Dev 6: 2248-2257.
31. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA. 2010. p53 is a direct transcrip-tional target of MYCN in neuroblastoma. Cancer Res 70: 1377-1388.
32. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al. 2008. On-cogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
33. Cheng NC, Van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, Versteeg R. 1995. Deletion mapping in neu-roblastoma cell lines suggeststwo distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene 10: 291-297.
34. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. 2008. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10: 1268-1274.
35. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. 2006. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neu-roblastoma. Cancer Res 66: 8139-8146.
36. Cheung NKV, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, et al. 2012. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307: 1062-1071.
37. Ciani E, Severi S, Contestabile A, Bartesaghi R, Contestabile A. 2004. Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. J Cell Sci 117: 4727-4737.
38. Cinatl J, Cinatl J, Mainke M, Weissflog A, Rabenau H, Korn-huber B, Doerr HW. 1993. In vitro differentiation of human neuroblastoma cells induced by sodium phenylace-tate. Cancer Lett 70: 15-24.
39. Clark O, Schmidt F, Coles CH, Tchetchelnitski V, Stoker AW. 2012. Functional analysis of the putative tumor suppres-sor PTPRD in neuroblastoma cells. Cancer Invest 30: 422-432.
40. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, et al. 2011. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci 108: 3336-3341.
41. Corvetta D, Chayka O, Gherardi S, D'Acunto CW, Cantilena S, Valli E, Piotrowska I, Perini G, Sala A. 2013. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: Functional and therapeutic implications. J Biol Chem 288: 8332-8341.
42. Cotterman R, Knoepfler PS. 2009. N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b. PLoS One 4: e5799.
43. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. 1993. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7: 671-682.
44. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, et al. 2010. Meta-analysis of neuroblas-tomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16: 4353-4362.
45. De La Fuente R, Baumann C, Viveiros MM. 2011. Role of ATRX in chromatin structure and function: Implications for chromosome instability and human disease. Reproduction 142: 221-234.
46. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
47. Dewitt J, Ochoa V, Urschitz J, Elston M, Moisyadi S, Nishi R. 2013. Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line. Oncogene. doi: 10.1038/onc.2013.39.
48. Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, Diamond M, Carpenter EL, Winter C, Lee H, et al. 2012. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 44: 1126-1130.
49. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, et al. 1999. Metastatic sites in stage IVand IVS neuroblas-toma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21: 181-189.
50. Dungwa JV, Uparkar U, May MT, Ramani P. 2012. Angioge-nin up-regulation correlates with adverse clinicopatho-logical and biological factors, increased microvascular density and poor patient outcome in neuroblastomas. Histopathology 60: 911-923.
51. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ike-gaki N, Brodeur GM. 2001. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-in-duced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319.
52. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P. 1995. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mam- mary carcinomas in transgenic mice. Oncogene 11: 181-190.
53. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
54. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, et al. 2011. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 10: 2115-2123.
55. Farrell AS, Sears RC. 2014. MYC degradation. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014365.
56. Fotsis T, Breit S, Lutz W, Rössler J, Hatzi E, Schwab M, Schweigerer L. 1999. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur J Biochem 263: 757-764.
57. Fulda S, Lutz W, Schwab M, Debatin KM. 2000. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med Pediatr Oncol 35: 582-584.
58. Fulda S, Poremba C, Berwanger B, Häcker S, Eilers M, Chris-tiansen H, Hero B, Debatin KM. 2006. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66: 10016-10023.
59. Gamble LD, Kees UR, Tweddle DA, Lunec J. 2012. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 31: 752-763.
60. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al. 2008. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
61. Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S, Nolte I, Savelyeva L, Bell E, Westermann F. 2013. CDK4 inhibition restores G1-S arrest in MYCN-amplified neuroblastoma cells in the context of doxoru-bicin-induced DNA damage. Cell Cycle 12: 1091-1104.
62. Golubovskaya VM, Finch R, Kweh F, Massoll NA, Campbell-Thompson M, Wallace MR, Cance WG. 2008. p53 regulates FAK expression in human tumor cells. Mol Carcinog 47: 373-382.
63. Gómez-Casares MT, García-Alegria E, López-Jorge CE, Fer-rándiz N, Blanco R, Alvarez S, Vaqué JP, Bretones G, Caraballo JM, Sánchez-Bailón P, et al. 2013. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). Oncogene 32: 2239-2246.
64. Gonzalez-Gomez P, Bello MJ, Lomas J, Arjona D, Alonso ME, Amiñoso C, Lopez-Marin I, Anselmo NP, Sarasa JL, Gutierrez M, et al. 2003. Aberrant methylation of multiple genes in neuroblastic tumours. Relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 39: 1478-1485.
65. Goodman LA, Liu BC, Thiele CJ, Schmidt ML, Cohn SL, Yamashiro JM, Pai DS, Ikegaki N, Wada RK. 1997. Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis 15: 130-139.
66. Gu L, Zhang H, He J, Li J, Huang M, Zhou M. 2012. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene 31: 1342-1353.
67. Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschellá G, Sala A. 2010. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget 1: 278-288.
68. Gustafson WC, Weiss WA. 2010. Myc proteins astherapeutic targets. Oncogene 29: 1249-1259.
69. Han S, Wada RK, Sidell N. 2001. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxi-some proliferator-activated receptor g. Cancer Res 61: 3998-4002.
70. Hartl M, Mitterstiller AM, Valovka T, Breuker K, Hobmayer B, Bister K. 2010. Stem cell-specific activation of an ancestral myc protooncogene with conserved basic functions in the early metazoan Hydra. Proc Natl Acad Sci 107: 4051-4056.
71. Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alborán IM, Olson JM, Eisenman RN. 2006. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 66: 8655-8661.
72. Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H, Murphy C, Schweigerer L, Fotsis T. 2000. MYCN onco-gene and angiogenesis: Down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. Adv Exp Med Biol 476: 239-248.
73. Hatzi E, Murphy C, Zoephel A, Ahorn H, Tontsch U, Bam-berger A-M, Yamauchi-Takihara K, Schweigerer L, Fotsis T. 2002a. N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. Eur J Biochem 269: 3732-3741.
74. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, et al. 2002b. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angio-genesis and suppresses neuroblastoma tumor growth. Oncogene 21: 3552-3561.
75. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, et al. 2011. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6: e18064.
76. Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, Flægstad T, Einvik C. 2011. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Dev Biol 11: 1.
77. Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. 2005. A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep 6: 177-183.
78. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, et al. 2012. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 4: 141-191.
79. Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Fukuba I, Mat-suura Y, Yokoyama T. 2001. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1. Med Pediatr Oncol 36: 67-74.
80. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. 2002. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62: 6462-6466.
81. Hossain MS, Ozaki T, Wang H, Nakagawa A, Takenobu H, Ohira M, Kamijo T, Nakagawara A. 2008. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma. Oncogene 27: 6075-6082.
82. Hossain S, Takatori A, Nakamura Y, Suenaga Y, Kamijo T, Nakagawara A. 2012. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo. Cancer Res 72: 4587-4596.
83. Huang R, Cheung NKV, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG. 2011. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J 25: 4138-4149.
84. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. 1994. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev 8: 1270-1284.
85. Iolascon A, Borriello A, Giordani L, Cucciolla V, Moretti A, Monno F, Criniti V, Marzullo A, Criscuolo M, Ragione FD. 2003. Caspase 3 and 8 deficiency in human neuro-blastoma. Cancer Genet Cytogenet 146: 41-47.
86. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Valle Della G, et al. 2011. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 71: 404-412.
87. Izumi H, Kaneko Y. 2012. Evidence of asymmetric cell division and centrosome inheritance in human neuroblasto-ma cells. Proc Natl Acad Sci 109: 18048-18053.
88. Janoueix-Lerosey I, Lequin D, Brugiéres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleier-macher G, Pierron G, et al. 2008. Somatic and germline activating mutations of the ALK kinase receptor in neu-roblastoma. Nature 455: 967-970.
89. Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P. 2008. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27: 2910-2922.
90. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. 2008. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 27: 3999-4007.
91. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. 2006. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Bio-chem Biophys Res Commun 351: 192-197.
92. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C, Finkelstein D, Qu C, Pounds S, Ellison DW, et al. 2012. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21: 168-180.
93. Kenney AM, Cole MD, Rowitch DH. 2003. Nmyc upregu-lation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130: 15-28.
94. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al. 2013. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates ofself-renewal. Proc Natl Acad Sci 110: 6021-6026.
95. Kim SS, Shago M, Kaustov L, Boutros PC, Clendening JW, Sheng Y, Trentin GA, Barsyte-Lovejoy D, Mao DYL, Kay R, et al. 2007. CUL7 is a novel antiapoptotic oncogene. Cancer Res 67: 9616-9622.
96. Knoepfler PS, Cheng PF, Eisenman RN. 2002. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neu-ronal differentiation. Genes Dev 16: 2699-2712.
97. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. 2006. Myc influences global chroma-tin structure. EMBO J 25: 2723-2734.
98. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW. 1983. Transposition and amplification of onco-gene-related sequences in human neuroblastomas. Cell 35: 359-367.
99. Kohl NE, Legouy E, DePinho RA, Nisen PD, Smith RK, Gee CE, Alt FW. 1986. Human N-myc is closely related in organization and nucleotide sequence to c-myc. Nature 319: 73-77.
100. Komuro H, Valentine MB, Rowe ST, Kidd VJ, Makino S, Brodeur GM, Cohn SL, Look AT. 1998. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma. J Pe-diatr Surg 33: 1695-1698.
101. Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ. 2007a. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Cancer Lett 256: 218-228.
102. Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ. 2007b. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer 43: 2413-2422.
103. INK4a tumor suppressor gene. Genes Dev 21: 49-54.
104. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yo-kota Y, Inserra A, Iavarone A. 2002. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 62: 301-306.
105. Lasorella A, Iavarone A, Israel MA. 1996. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol 16: 2570-2578.
106. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. 2000. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407: 592-598.
107. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, Knoepfler PS, Cheng PF, MacDon-ald HR, Eisenman RN, et al. 2008. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 3: 611-624.
108. Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío I, Castresana JS. 2006. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 6: 254.
109. Liu T, Tee AEL, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, et al. 2007. Activation of tissue transglutaminase transcription by histone deacety-lase inhibition as a therapeutic approach for Myc onco-genesis. Proc Natl Acad Sci 104: 18682-18687.
110. Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M. 2010. MYCN-regulated microRNAs repress estrogen receptor-a (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci 107: 1553-1558.
111. Lutterbach B, Hann SR. 1994. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14: 5510-5522.
112. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al. 2010. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
113. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA, Alt FW. 2000. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14: 1390-1399.
114. Maris JM, Hogarty MD, Bagatell R, Cohn SL. 2007. Neuro-blastoma. Lancet 369: 2106-2120.
115. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, et al. 2010. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29: 5957-5968.
116. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E, Ling D, Thomas W, et al. 2011. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 7: e1002135.
117. Matsumoto M, Akiyama T, Miyatake S, Oda Y, Kikuchi H, Hanaoka M, Namba Y. 1989. Expression of proto-onco-gene products during drug-induced differentiation of a neuroblastoma cell line SK-N-DZ. Acta Neuropathol 79: 217-221.
118. Matthay KK, George RE, Yu AL. 2012. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18: 2740- 2753.
119. Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AWM, et al. 2012. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer 11: 6.
120. Megison ML, Stewart JE, Nabers HC, Gillory LA, Beierle EA. 2012. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis 18: 2740-2753.
121. Meitar D, Crawford SE, Rademaker AW, Cohn SL. 1996. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neu-roblastoma. J Clin Oncol 14: 405-414.
122. Meyer N, Penn LZ. 2008. Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
123. Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, et al. 2012a. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44: 1199-1206.
124. Molenaar JJ, Koster J, Zwijnenburg DA, van SluisP, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, et al. 2012b. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593.
125. Mossé YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM. 2007. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 46: 936-949.
126. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930-935.
127. Mueller S, Matthay KK. 2009. Neuroblastoma: Biology and staging. Curr Oncol Rep 11: 431-438.
128. Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, Beisel C, Gogolin S, Fischer M, Henrich KO, et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res 70: 3791-3802.
129. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. 2010. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci 107: 14152-14157.
130. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. 1994. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14: 759-767.
131. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fu-kuzawa M. 2007. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 30: 1189-1196.
132. Nguyen LB, Diskin SJ, Capasso M, Wang K, Diamond MA, Glessner J, Kim C, Attiyeh EF, Mossé YP, Cole K, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 7: e1002026.
133. Noujaim D, van Golen CM, van Golen KL, Grauman A, Feldman EL. 2002. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblas-toma cells. Oncogene 21: 4549-4557.
134. Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M, Okimoto Y, Fujimura Y, Koseki H, Kohno Y, et al. 2010. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bband TSLC1 in neuroblastoma. Oncogene 29: 2681-2690.
135. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, et al. 2009. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15: 67-78.
136. Ozer E, Altungoz O, Unlu M, Aygun N, Tumer S, Olgun N. 2007. Association of MYCN amplification and 1p dele-tionin neuroblastomas with high tumor vascularity. Appl Immunohistochem Mol Morphol 15: 181-186.
137. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read T-A, Sun JL, et al. 2012. An animal model of MYC-driven medulloblastoma. Cancer Cell 21: 155-167.
138. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. 1997. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 150: 81-89.
139. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al. 2013. The genetic landscape of high-risk neuroblas-toma. Nat Genet 45: 279-284.
140. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, et al. 2012. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488: 106-110.
141. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, et al. 2013. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3: 308-323.
142. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR. 1994. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9: 59-70.
143. Raschella G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, Tonini GP, De Bernardi B, Calabretta B. 1999. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Cancer Res 59: 3365-3368.
144. Reddy CD, Patti R, Guttapalli A, Maris JM, Yanamandra N, Rachamallu A, Sutton LN, Phillips PC, Posner GH. 2006. Anticancer effects of the novel 1a, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblasto-ma. J Cell Biochem 97: 198-206.
145. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M. 2002. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overex-pression. Int J Cancer 102: 351-354.
146. Rosenbaum H, Webb E, Adams JM, Cory S, Harris AW. 1989. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. EMBO J 8: 749-755.
147. Roussel MF, Robinson GW. 2013. Role of MYC in medullo-blastoma. Cold Spring Harb Perspect Med doi: 10.1101/ cshperspect.014308.
148. Sabó A, Amati B. 2014. Genome recognition by Myc. Cold Spring Harb Perspect Med doi: 10.1101/cshper-spect.014191.
149. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, et al. 2013. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuro-blastoma. Nat Genet 45: 12-17.
150. Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H. 1993. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 117: 1445-1455.
151. Schönherr C, Ruuth K, Kamaraj S, Wang C-L, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, et al. 2012. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 31: 5193-5200.
152. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, et al. 2012. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 32: 1059-1065.
153. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. 1983. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248.
154. Schwab M, Varmus HE, Bishop JM. 1985. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature 316: 160-162.
155. Schwartzentruber J, Korshunov A, Liu XY, Jones DTW, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DAK, Tonjes M, et al. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes inpaediatricglio-blastoma. Nature 482: 226-231.
156. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501- 2514.
157. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. 1985. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
158. Seth A, Alvarez E, Gupta S, Davis RJ. 1991. A phosphoryla-tion site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression. J Biol Chem 266: 23521-23524.
159. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA, David RD, Vasudevan SA, Yang J, Nuchtern JG. 2009. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 8: 2461-2469.
160. Shioda N, Beppu H, Fukuda T, Li E, Kitajima I, Fukunaga K. 2011. Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J Neurosci 31: 346-358.
161. Sidell N. 1982. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 68: 589-596.
162. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM. 2005. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 9: 327-338.
163. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. 2005. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci 102: 731-736.
164. Slavc I, Ellenbogen R, Jung WH, Vawter GF, Kretschmar C, Grier H, Korf BR. 1990. myc Gene amplification and expression in primary human neuroblastoma. Cancer Res 50: 1459-1463.
165. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. 2007. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 117: 2702-2712.
166. Stanton LW, Schwab M, Bishop JM. 1986. Nucleotide sequence of the human N-myc gene. Proc Natl Acad Sci 83: 1772-1776.
167. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. 1992. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 6: 2235-2247.
168. Strasser A, Harris AW, Bath ML, Cory S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
169. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. 2001. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155: 459-470.
170. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA. 2006. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95-99.
171. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, et al. 2010. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 16: 1134-1140.
172. Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, et al. 2012. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 21: 601-613.
173. Tanaka N, Fukuzawa M. 2008. MYCN downregulates integ-rin a1 to promote invasion of human neuroblastoma cells. Int J Oncol 33: 815-821.
174. Teitz T, Inoue M, Valentine MB, Zhu K, Rehg JE, Zhao W, Finkelstein D, Wang Y-D, Johnson MD, Calabrese C, et al. 2013. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res 73: 4086-4097.
175. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. 2000. Caspase 8 is deleted or silenced preferentially in childhood neu-roblastomas with amplification of MYCN. Nat Med 6: 529-535.
176. Thiele CJ, Reynolds CP, Israel MA. 1985. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313: 404-406.
177. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. 2001. p53 cellular localization and function in neuroblas-toma: Evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 158: 2067-2077.
178. Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R. 2005. Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res 65: 3136-3145.
179. Valli E, Trazzi S, Fuchs C, Erriquez D, Bartesaghi R, Perini G, Ciani E. 2012. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiationof neuronal cells. Biochim Biophys Acta 1819: 1173-1185.
180. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P, Puisieux A. 2004. Oncogenic cooperation between H-Twist and NMyc overrides failsafe programs in cancer cells. Cancer Cell 6: 625-630.
181. van Golen CM, Soules ME, Grauman AR, Feldman EL. 2003. N-Myc overexpression leads to decreased b1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 22: 2664-2673.
182. Varlakhanova NV, Cotterman RF, deVries WN, Morgan J, Donahue LR, Murray S, Knowles BB, Knoepfler PS. 2010. myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation 80: 9-19.
183. Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H. 1997. Regulation of the neural crest cell fate by N-myc: Promotion of ventral migration and neuronal differentiation. Development 124: 1953-1962.
184. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, et al. 2011. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469: 216-220.
185. Wiese K, Walz S, von Eyss B, Wolf E, Athineos D, Sansom O, Eilers M. 2013. The role of MIZ1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.014290.
186. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. 1997. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995.
187. Welcker M, Orian A, Jin J, Grim JE, Grim JA, Harper JW, Eisenman RN, Clurman BE. 2004. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci 101: 9085-9090.
188. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, et al. 2008. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
189. Wright JH. 1910. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 12: 556-561.
190. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al. 2012. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44: 251-253.
191. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y. 2005. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 11: 4321-4330.
192. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI. 2004. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116-2125.
193. Yancopoulos GD, Nisen PD, Tesfaye A, Kohl NE, Goldfarb MP, Alt FW. 1985. N-myc can cooperate with ras to transform normal cells in culture. Proc Natl Acad Sci 82: 5455-5459.
194. Zaizen Y, Taniguchi S, Noguchi S, Suita S. 1993. The effect of N-myc amplification and expression on invasiveness of neuroblastoma cells. J Pediatr Surg 28: 766-769.
195. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, et al. 2009. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res 15: 4630-4640.
196. Zhao X, D'Arca D, Lim WK, Brahmachary M, Carro MS, Ludwig T, Cardo CC, Guillemot F, Aldape K, Califano A, et al. 2009. The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev Cell 17: 210-221.
197. Zhu S, Lee J-S, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H, et al. 2012. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21: 362-373.
198. Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, Nau MM, Witte ON, Toran-Allerand D, Gee CE. 1986. Differential expression of myc family genes during murine development. Nature 319: 780-783